Literature DB >> 20959533

Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet.

Mikael Bjursell1, Therése Admyre, Melker Göransson, Anna E Marley, David M Smith, Jan Oscarsson, Mohammad Bohlooly-Y.   

Abstract

Free fatty acid receptor 2 (Ffar2), also known as GPR43, is activated by short-chain fatty acids (SCFA) and expressed in intestine, adipocytes, and immune cells, suggesting involvement in lipid and immune regulation. In the present study, Ffar2-deficient mice (Ffar2-KO) were given a high-fat diet (HFD) or chow diet and studied with respect to lipid and energy metabolism. On a HFD, Ffar2-KO mice had lower body fat mass and increased lean body mass. The changed body composition was accompanied by improved glucose control and lower HOMA index, indicating improved insulin sensitivity in Ffar2-KO mice. Moreover, the Ffar2-KO mice had higher energy expenditure accompanied by higher core body temperature and increased food intake. The liver weight and content of triglycerides as well as plasma levels of cholesterol were lower in the Ffar2-KO mice fed a HFD. A histological examination unveiled decreased lipid interspersed in brown adipose tissue of the Ffar2-KO mice. Interestingly, no significant differences in white adipose tissue (WAT) cell size were observed, but significantly lower macrophage content was detected in WAT from HFD-fed Ffar2-KO compared with wild-type mice. In conclusion, Ffar2 deficiency protects from HFD-induced obesity and dyslipidemia at least partly via increased energy expenditure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959533     DOI: 10.1152/ajpendo.00229.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  110 in total

Review 1.  Gut microbiome, obesity, and metabolic dysfunction.

Authors:  Herbert Tilg; Arthur Kaser
Journal:  J Clin Invest       Date:  2011-06-01       Impact factor: 14.808

Review 2.  Brown and beige fat: development, function and therapeutic potential.

Authors:  Matthew Harms; Patrick Seale
Journal:  Nat Med       Date:  2013-09-29       Impact factor: 53.440

Review 3.  Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health.

Authors:  Connie W Y Ha; Yan Y Lam; Andrew J Holmes
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 4.  Gut microbiota: a new path to treat obesity.

Authors:  Giovanna Muscogiuri; Elena Cantone; Sara Cassarano; Dario Tuccinardi; Luigi Barrea; Silvia Savastano; Annamaria Colao
Journal:  Int J Obes Suppl       Date:  2019-04-12

Review 5.  Role of Short Chain Fatty Acid Receptors in Intestinal Physiology and Pathophysiology.

Authors:  Medha Priyadarshini; Kumar U Kotlo; Pradeep K Dudeja; Brian T Layden
Journal:  Compr Physiol       Date:  2018-06-18       Impact factor: 9.090

Review 6.  Gut Microbiota and Obesity: Potential Therapeutic Targets and Probiotic Treatment.

Authors:  Nicole D White
Journal:  Am J Lifestyle Med       Date:  2015-11-24

7.  Effect of GPR84 deletion on obesity and diabetes development in mice fed long chain or medium chain fatty acid rich diets.

Authors:  Eugene Du Toit; Liam Browne; Helen Irving-Rodgers; Helen M Massa; Nicolette Fozzard; Michael P Jennings; Ian R Peak
Journal:  Eur J Nutr       Date:  2017-04-20       Impact factor: 5.614

8.  Gut bacteria-host metabolic interplay during conventionalisation of the mouse germfree colon.

Authors:  Sahar El Aidy; Muriel Derrien; Claire A Merrifield; Florence Levenez; Joël Doré; Mark V Boekschoten; Jan Dekker; Elaine Holmes; Erwin G Zoetendal; Peter van Baarlen; Sandrine P Claus; Michiel Kleerebezem
Journal:  ISME J       Date:  2012-11-22       Impact factor: 10.302

Review 9.  Gut microbiota-generated metabolites in animal health and disease.

Authors:  Won-Jae Lee; Koji Hase
Journal:  Nat Chem Biol       Date:  2014-06       Impact factor: 15.040

Review 10.  Microbiota and metabolic diseases.

Authors:  Alessia Pascale; Nicoletta Marchesi; Cristina Marelli; Adriana Coppola; Livio Luzi; Stefano Govoni; Andrea Giustina; Carmine Gazzaruso
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.